Therefore, we postulated that the perifoveal degeneration observed in the mother may be a result from perifoveal vascular abnormality. This is consistent with our previous report 5 that NF-kB signalling is closely associated with retinal angiogenesis. In contrast, phenotypic variations suggest the presence of other genetic factors.
It was recently reported that in the West, an identical genomic deletion accounted for 90% of the identified mutations in the NEMO gene. Because the same gene deletion was found in Japanese, the deletion may be the most common mutational hot spot irrespective of race, although further genetic analysis of Japanese IP patient is required. We agree with Canning and Lotery 1 that a clinical trial of bevacizumab in the treatment of neovascular age-related macular degeneration (AMD) could reveal important safety issues, but for rarer diseases randomised controlled trials are not always appropriate.
Neovascular glaucoma is another disease where bevacizumab is promising. It is, however, uncommon compared with AMD, and fortunately most cases respond to panretinal photocoagulation (PRP) when timely performed. 2 For the minority in whom PRP is either not possible or not effective, the prognosis is dire.
Bevacizumab has several possible roles in the management of this vexing condition. Used early it may prevent intractable glaucoma; later when the angle is closed, it may be used as an adjunct to glaucoma drainage surgery reducing the risk of intraocular bleeding. Finally by causing regression of new vessels and reducing leakage of inflammatory mediators, it may help in the treatment of painful blind eyes. Faced with the alternatives of a painful blind eye or enucleation, patients are unlikely to be willing to accept the control arm of a trial, nor would we be willing to offer it.
On this basis we have been given approval by our Regional Ethics Committee to use bevacizumab for the treatment of neovascular glaucoma unresponsive to PRP. Where randomised placebo-controlled clinical trials are not appropriate, one should not underestimate the power of a well-conducted, prospective, observational case series. We wish to thank Franks for her insightful contribution to the debate on the indications and evidence for the use of bevacizumab in the eye.
One of the prerequisites for an ethical randomised controlled trial is the state of clinical equipoiseFthe researchers should not be biased strongly in favour of one treatment option or the other. 1 This implies a degree of uncertainty regarding the outcome for both treatment options.
Unfortunately there is little doubt about the natural history of rubeotic glaucoma unresponsive to laser. It is a dire condition with devastating consequences for the quality of the patient's life and their family. It is only natural to wish to do everything one can under such conditions. There is a good theoretical basis for the use of bevacizumab in this condition and so far the safety profile seems good.
We agree with Franks therefore that ranibizumab or bevacizumab in rubeotic glaucoma would be justified in the context of a carefully documented observational study. The wholesale use of this drug in a raft of conditions where other options exist remains a cause for comment. Bevacizumab might well be a very effective and cost-effective drug for much vascular eye pathologyFlet's just prove it! Retinal pigment epithelium (RPE) tear mostly occurs as a complication of age-related macular degeneration but may also develop as a rare complication after trauma. [1] [2] [3] [4] [5] Patients with traumatic RPE tear involving the fovea usually have poor visual prognosis. 1, 2 We report the spontaneous resolution of traumatic RPE tears and pigment epithelial detachment (PED) in a patient after blunt trauma who subsequently had good visual recovery.
Case report
A 63-year-old woman presented with left blurred vision after being hit by a badminton racquet. Her left eye
